Carboxy-PTIO
Based on 7 publication(s) in Google Scholar
Carboxy-PTIO is a potent nitric oxide (NO) scavenger that can make a quick reaction with NO to produce NO2. Carboxy-PTIO can prevent hypotension and endotoxic shock through the direct scavenging action against NO in lipopolysaccharide-stimulated rat model.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 145757-47-7
- Formule: C14H17N2O4
- Masse moléculaire:277.30
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Carboxy-PTIO
More- Neurosci Bull. 2025 Jun 28. [Abstract]
- Antioxid Redox Signal. 2023 Apr;38(10-12):747-767. [Abstract]
- Int Immunopharmacol. 2026 Feb 1:170:116055. [Abstract]
- iScience. 2023 Jul 10;26(8):107353. [Abstract]
- Toxicol Appl Pharmacol. 2024 May 20:487:116976. [Abstract]
- Int J Radiat Biol. 2025;101(4):341-350. [Abstract]
- Pharmacological Research-Modern Chinese Medicine. 2024 Mar, 10, 100365.
Activité biologique
Description
In Vitro
Carboxy-PTIO (200 μM; 1 h prior to physalin A; 24 hours) significantly suppresses the stimulation of NO expression induced by physalin A treatment, but no change is observed in Carboxy-PTIO treatment alone[1]. Carboxy-PTIO (200 μM; 1 h prior to physalin A; 24 hours) reduces physalin A-induced cleavage of procaspase-3 and PARP, down-regulated ICAD expression,diminishing DNA fragmentation in nuclei[1]. Carboxy-PTIO (200 μM; 1 h prior to physalin A; 24 hours) shows no effect on iNOS expression. However, decreased-mTOR and p-mTOR levels induced by physalin A is reversed by Carboxy-PTIO with concomitant suppression of LC3 I to LC3 II conversions in A375-S2 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A375-S2 cells
-
Concentration:200 μM
-
Incubation Time:1 h prior to physalin A; 24 hours
-
Result:Diminished physalin A-induced procaspase-3 and PARP cleavage.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SD rats[3]
-
Dosage:0.056-1.70 mg/kg/min
-
Administration:Intravenous injection; 0.056-1.70 mg/kg/min; infused for 1 hr beginning 90 min after the LPS injection 90 min
-
Result:Exhibited a potent therapeutic value in endotoxin shock through the direct scavenging action against NO.
Chemical Information
-
CAS No. 145757-47-7
-
Masse moléculaire 277.30
-
Formule C14H17N2O4
-
SMILES
[O]N1C(C)(C)C(C)(C)[N+]([O-])=C1C2=CC=C(C(O)=O)C=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Neurosci Bull
2025 Jun 28. PMID: 40580390 -
Antioxid Redox Signal
Radiation-induced bystander effect on the genome of bone marrow mesenchymal stem cells in lung cancer. [Abstract]2023 Apr;38(10-12):747-767. PMID: 36242096 -
Int Immunopharmacol
Targeting periodontal inflammatory microenvironment to ameliorate periodontitis: A nitrogen ions implantation technique. [Abstract]2026 Feb 1:170:116055. PMID: 41448003 -
iScience
2023 Jul 10;26(8):107353. PMID: 37529099 -
Toxicol Appl Pharmacol
RGS2 attenuates alveolar macrophage damage by inhibiting the Gq/11-Ca2+ pathway during cowshed PM2.5 exposure, and aberrant RGS2 expression is associated with TLR2/4 activation. [Abstract]2024 May 20:487:116976. PMID: 38777097 -
Int J Radiat Biol
Evaluation of the influence of radiation-induced cohort effect in cell populations receiving different doses. [Abstract]2025;101(4):341-350. PMID: 39899278 -
Protocole
-
How to Select a Suitable Non-Mouse Animal Model
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification. Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures. Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition. Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use.
-
How to Choose the Right Model Animal
Choosing the right model animal is a validity-driven decision in which the species, strain, sex, age, genetic background, disease-induction method, outcome measures, and welfare burden must match the scientific question rather than laboratory tradition or convenience. A model should be selected by judging face validity, construct validity, and predictive validity: whether it resembles the human phenotype, whether it reproduces relevant mechanisms, and whether results are likely to predict human biology or treatment response. Animal studies often fail to translate because of species differences, weak disease resemblance, poor experimental design, inadequate reporting, publication bias, and underuse of randomization, blinding, and sample-size justification. Unresolved questions include how to rank competing models objectively, how much human-disease complexity must be reproduced for a given objective, and when non-animal systems such as organoids, ex vivo tissue, or computational models
Pureté et documentation
Références
[1]. Hao He, et al.Nitric oxide induces apoptosis and autophagy; autophagy down-regulates NO synthesis in physalin A-treated A375-S2 human melanoma cells.Food Chem Toxicol. 2014 Sep;71:128-35. [Content Brief]
[2]. T Akaike, et al. Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry. 1993 Jan 26;32(3):827-32. [Content Brief]
[3]. M Yoshid, et al. Therapeutic effects of imidazolineoxyl N-oxide against endotoxin shock through its direct nitric oxide-scavenging activity. Biochem Biophys Res Commun. 1994 Jul 29;202(2):923-30. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)